Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients (2021) Persa OD, Schatton K, Rübben A, Berking C, Erdmann M, Schlaak M, Mauch C, Steeb T Journal article Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors (2021) Stuermer SH, Lechner A, Berking C Journal article Primary Biliary Cirrhosis and Granulomatous Hepatitis after Immune Checkpoint Blockade in Patients with Metastatic Melanoma: Report of 2 Cases and Literature Discussion (2021) Ruini C, Haas C, Mastnik S, Knott M, French LE, Schlaak M, Berking C Journal article Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy (2021) Koch EA, Nickel FT, Heinzerling L, Schulz YK, Berking C, Erdmann M Journal article Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11 (2019) Duell J, Lukic DS, Karg M, Reusch U, Koch J, Zhukovsky EA, Rajkovic E, et al. Journal article Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy (2018) Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L Journal article Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab (2015) Uslu U, Agaimy A, Hundorfean G, Harrer T, Schuler G, Heinzerling L Journal article Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions (2014) Eigentler TK, Schlaak M, Hassel JC, Loquai C, Stoffels I, Gutzmer R, Paetzold S, et al. Journal article Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. (2010) Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu FS, Schwemmlein M, et al. Journal article, Original article